This technology is a combinatorial strategy that allows exploration of pairwise genetic interactions by directing CRISPR/Cas9 to edit multiple targets simultaneously.
The CRISPR/Cas9 system has become a prominent way for researchers and clinicians alike to efficiently modify the genome, and has applications ranging from genetically engineered crops to personalized medicine. However, to properly probe genetic interactions, it is crucial to interrogate multiple chromosomal sites at once. There remains a need for a high-throughput, combinatorial method that would allow for this type of multiplex investigation.
The multiplex strategy for assessing genetic interactions using CRISPR-Cas9, or MoSAIC, provides a high-throughput method for simultaneously editing genomic information at multiple sites. This is achieved in a single step by rapid creation of an exhaustive library of guide RNA pairs which allow for investigation of all possible pairwise interactions within a set of genetic loci. This system represents a significant advancement in combinatorial gene editing, with wide ranging applications from personalized clinical treatment to multifaceted understanding of disease.
This technology has been validated in human embryonic kidney cells.
Patent Pending (WO/2017/069829)
IR CU15290
Licensing Contact: Cynthia Lang